In drug delivery systems, validation is executed under tightly controlled and well-defined conditions. Material batches are within specification, process parameters are fixed, environmental variables are stabilised, and device behaviour is measured against predefined acceptance criteria. This framework is essential for regulatory approval and functional verification, but it represents a constrained snapshot of performance. It does not capture the full range of variability that a device will encounter once it transitions into serial production and real-world use.
In production, variability is inherent and cumulative. Polymer properties shift within allowable tolerances between batches. Tooling undergoes gradual wear, affecting surface finish, dimensional accuracy, and part consistency. Process parameters such as temperature, pressure, and cycle time experience small but continuous drift, even in statistically controlled environments. These factors do not individually exceed limits, but together they create a dynamic system in which component behaviour evolves over time. The design remains nominally identical, yet its functional response begins to depend on how robustly it accommodates this variation.
These effects become visible at the level of interfaces and repeated interactions. Friction coefficients are not static; they change with surface conditioning, lubrication state, and cycle count. Elastomeric seals respond to compression set, relaxation, and exposure to media, which alters their sealing behaviour over time. Flow characteristics in micro-scale channels or dosing paths are sensitive to minor geometric deviations and surface energy changes. As a result, dosing accuracy is no longer defined solely by the initial design geometry, but by the system’s ability to maintain consistent behaviour across cycles, batches, and environmental conditions.
This is where validation results can diverge from field performance. A device that meets all functional and regulatory requirements during validation can still exhibit variability in delivered volume, actuation force, or sealing performance during extended use. These deviations are often gradual and distributed, making them difficult to detect in early-stage testing, yet they accumulate into measurable performance shifts at scale. In drug delivery applications, where repeatability and precision are directly linked to therapeutic outcomes, this gap between validated and sustained performance is critical.
Designing for reliability therefore requires a broader engineering perspective. Material selection must account not only for initial properties, but for long-term mechanical and chemical behaviour under cyclic loading and environmental exposure. Interface design must consider how contact surfaces evolve with wear, including changes in friction, adhesion, and deformation. Tolerance strategies must be robust against process variation, ensuring functional consistency even at the edges of specification. Process design must focus on stability over time, not just capability at start-up, with controls that limit drift and maintain repeatability across high-volume production.
An integrated approach that connects design, material science, tooling, and manufacturing is required to manage these interactions effectively. Early co-engineering allows potential failure modes to be identified and mitigated before they manifest in production. Simulation and testing should extend beyond initial validation to include ageing, cyclic loading, and worst-case process conditions. Inline quality control and traceability provide the data needed to monitor performance trends and intervene before deviations impact functionality. This aligns with the broader requirement for precision and reliability in system-critical components, where performance must remain stable over the full product lifecycle.
Performance, in this context, is a statistical outcome rather than a single-point measurement. It is defined by consistency across millions of cycles, across multiple production batches, and across varying use conditions. Validation demonstrates that a design can meet its requirements under controlled conditions. Sustained performance in production and use demonstrates that it will continue to meet those requirements over time.
That distinction determines whether a design is ready for real-world application.
Where does performance start to drift once your device leaves validation and enters production and real use? Let’s talk.